KR20220021451A - 안정성이 향상된 노로바이러스 유사 입자 - Google Patents

안정성이 향상된 노로바이러스 유사 입자 Download PDF

Info

Publication number
KR20220021451A
KR20220021451A KR1020217032648A KR20217032648A KR20220021451A KR 20220021451 A KR20220021451 A KR 20220021451A KR 1020217032648 A KR1020217032648 A KR 1020217032648A KR 20217032648 A KR20217032648 A KR 20217032648A KR 20220021451 A KR20220021451 A KR 20220021451A
Authority
KR
South Korea
Prior art keywords
pro
leu
val
gly
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217032648A
Other languages
English (en)
Korean (ko)
Inventor
프란지스카 쟈크조우스키
안드레 디에스너
프랑크 티메
Original Assignee
아이콘 제네틱스 지엠비에이치
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아이콘 제네틱스 지엠비에이치 filed Critical 아이콘 제네틱스 지엠비에이치
Publication of KR20220021451A publication Critical patent/KR20220021451A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020217032648A 2019-03-12 2020-03-11 안정성이 향상된 노로바이러스 유사 입자 Ceased KR20220021451A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19162266 2019-03-12
EP19162266.1 2019-03-12
PCT/EP2020/056461 WO2020182860A1 (en) 2019-03-12 2020-03-11 Norovirus-like particles with improved stability

Publications (1)

Publication Number Publication Date
KR20220021451A true KR20220021451A (ko) 2022-02-22

Family

ID=65818179

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217032648A Ceased KR20220021451A (ko) 2019-03-12 2020-03-11 안정성이 향상된 노로바이러스 유사 입자

Country Status (10)

Country Link
US (1) US20220152186A1 (https=)
EP (1) EP3938378B1 (https=)
JP (2) JP7536031B2 (https=)
KR (1) KR20220021451A (https=)
CN (1) CN113557240B (https=)
AU (1) AU2020235344B2 (https=)
ES (1) ES2953232T3 (https=)
IL (1) IL285914B2 (https=)
MX (1) MX2021011059A (https=)
WO (1) WO2020182860A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020235344B2 (en) * 2019-03-12 2024-10-24 Icon Genetics Gmbh Norovirus-like particles with improved stability
US20250002539A1 (en) * 2021-07-26 2025-01-02 The University Of North Carolina At Chapel Hill Methods and compositions for norovirus chimeric therapeutics
CN118252924A (zh) * 2022-12-27 2024-06-28 远大赛威信生命科学(南京)有限公司 用于诱发哺乳动物针对诺如病毒的免疫反应的药物组合物及其制备方法和用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1025234A1 (en) 1997-10-24 2000-08-09 E.I. Du Pont De Nemours And Company Binary viral expression system in plants
EP1115870A2 (en) 1998-09-23 2001-07-18 E.I. Du Pont De Nemours And Company Binary viral expression system in plants
DE10109354A1 (de) 2001-02-27 2002-09-05 Icon Genetics Ag Rekombinante virale Schaltersysteme
DE10121283B4 (de) 2001-04-30 2011-08-11 Icon Genetics GmbH, 80333 Verfahren und Vektoren zur Amplifikation oder Expression von gewünschten Nucleinsäuresequenzen in Pflanzen
CN1533438A (zh) 2001-06-08 2004-09-29 �����Ŵ��Ƽ���˾ 在植物生产蛋白质的方法
AU2002314021B2 (en) 2002-04-30 2008-04-10 Icon Genetics Gmbh Amplification vectors based on trans-splicing
WO2006012906A1 (en) 2003-11-10 2006-02-09 Icon Genetics Ag Rna virus-derived plant expression system
ATE469231T1 (de) 2003-11-10 2010-06-15 Icon Genetics Gmbh Von rna-virus abgeleitetes pflanzenexpressionssystem
EP1564295A1 (en) 2004-01-23 2005-08-17 Icon Genetics AG RNA virus-derived plant expression system
EP1616959A1 (en) 2004-07-07 2006-01-18 Icon Genetics AG Biological safe transient protein expression in plants
CA2648886C (en) 2006-05-29 2015-10-20 Icon Genetics Gmbh Plant virus-based inducible expression system
EP1897953A1 (en) 2006-09-06 2008-03-12 Icon Genetics GmbH Potexvirus-derived replicon
SG10202012986SA (en) 2006-09-29 2021-01-28 Ligocyte Pharmaceuticals Inc Norovirus vaccine formulations
JP5846908B2 (ja) * 2009-05-28 2016-01-20 東洋紡株式会社 特性の改変されたグルコースデヒドロゲナーゼ
AU2011276328C1 (en) * 2010-07-06 2016-01-21 Novartis Ag Norovirus derived immunogenic compositions and methods
EP2418283A1 (en) 2010-08-07 2012-02-15 Nomad Bioscience GmbH Process of transfecting plants
EP2647715A1 (en) 2012-04-03 2013-10-09 Nomad Bioscience GmbH Agrobacterium for transient transfection of whole plants
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
CA2913068C (en) 2013-05-23 2023-01-10 Nomad Bioscience Gmbh Process of providing plants with abiotic stress resistance
US11208441B2 (en) * 2015-10-22 2021-12-28 Protenova Co., Ltd. Immunoglobulin-binding polypeptide
EP3601580A4 (en) * 2017-03-23 2021-01-06 Medicago Inc. NOROVIRUS FUSION PROTEINS AND VLPS WITH NOROVIRUS FUSION PROTEINS
AU2020235344B2 (en) * 2019-03-12 2024-10-24 Icon Genetics Gmbh Norovirus-like particles with improved stability

Also Published As

Publication number Publication date
EP3938378A1 (en) 2022-01-19
EP3938378C0 (en) 2023-08-02
IL285914A (en) 2021-10-31
JP2022522891A (ja) 2022-04-20
CN113557240B (zh) 2025-02-25
MX2021011059A (es) 2021-10-13
CA3133030A1 (en) 2020-09-17
AU2020235344A1 (en) 2021-09-23
JP7672460B2 (ja) 2025-05-07
EP3938378B1 (en) 2023-08-02
JP7536031B2 (ja) 2024-08-19
WO2020182860A1 (en) 2020-09-17
IL285914B1 (en) 2024-07-01
JP2024009801A (ja) 2024-01-23
US20220152186A1 (en) 2022-05-19
CN113557240A (zh) 2021-10-26
IL285914B2 (en) 2024-11-01
AU2020235344B2 (en) 2024-10-24
ES2953232T3 (es) 2023-11-08

Similar Documents

Publication Publication Date Title
JP7672460B2 (ja) 安定性が改善されたノロウイルス様粒子
US20230256078A1 (en) Immunogenic composition and vaccine for generating an immune response to norovirus
US20070128213A1 (en) Novel plant virus particles and methods of inactivation thereof
KR102288367B1 (ko) 식물체에서 바이러스-유사 입자를 발현하는 재조합 벡터 및 이를 이용한 써코바이러스-유사 입자를 포함하는 백신 조성물의 제조방법
US6730306B1 (en) Parvovirus vaccine as viral coat protein fusions
CN111727255A (zh) 修饰后诺如病毒vp1蛋白和包含修饰后诺如病毒vp1蛋白的vlp
CN112135630A (zh) 猪瘟疫苗组合物及其制备方法
US12357686B2 (en) Porcine epidemic diarrhea (PED) virus vaccine composition and preparation method thereof
KR20140039973A (ko) 노다바이러스의 바이러스 유사입자의 생산방법, 이를 발현하는 효모 세포주 및 이를 포함하는 백신 조성물
JP2023539356A (ja) 改変コロナウイルス構造タンパク質
CN111565747A (zh) 与猪fc片段融合的抗原，以及包含该抗原的疫苗组合物
CA3133030C (en) Norovirus-like particles with improved stability
Li et al. Morphology and stability changes of recombinant TMV particles caused by a cysteine residue in the foreign peptide fused to the coat protein
JP2021524273A (ja) 改変ノロウイルスｖｐ１タンパク質および改変ノロウイルスｖｐ１タンパク質を含むｖｌｐ
CN105085625A (zh) 一种兼抗肠道病毒71和柯萨奇病毒a16的基因工程疫苗
TWI412588B (zh) 重組病毒蛋白及顆粒
US12467058B2 (en) Influenza virus-like particle production in plants
KR20250059337A (ko) 니파 바이러스 NiV F-G 재조합 단백질 및 이의 용도
GB2591822A (en) Extracellular assembly of virus like particles
BR102018011834A2 (pt) polipeptídeo flaviviral com finalidade vacinal e diagnostica produzido em planta

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902